{"id":42901,"date":"2014-01-04T21:59:23","date_gmt":"2014-01-05T02:59:23","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=42901"},"modified":"2014-01-04T22:02:24","modified_gmt":"2014-01-05T03:02:24","slug":"caberet","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2014\/01\/04\/caberet\/","title":{"rendered":"caberet…"},"content":{"rendered":"\n

I think Deep Throat’s line, "Follow the money," was a bit of fiction from screenwriter William Goldman rather than historical fact, but it doesn’t matter. It captured a principle that may well outlive its origins. Here, Ginny Barbour uses it with finesse:<\/em><\/p>\n

\n
Follow the Money; or, Why it Took an Accounts Committee to Decide Why Access to Clinical Trial Data Matters<\/a><\/div>\n
PLoS blogs <\/font><\/strong><\/div>\n
By Virginia Barbour<\/div>\n
January 3, 2014<\/div>\n
Ginny Barbour, Medicine Editorial Director at PLOS, discusses a recently-published UK Government spending report on access to clinical trial information and the stockpiling of Tamiflu.<\/em><\/div>\n

<\/p>\n

Yesterday the UK Parliament’s Public Accounts Committee<\/a>, which monitors UK Government spending – focusing on “value-for-money criteria which are based on economy, effectiveness and efficiency” – published a rather amazing report; not just because of the topic of its enquiry but in particular its conclusions, which have implications well beyond the UK. The topic was “Access to clinical trial information and the stockpiling of Tamiflu<\/a>”: the conclusions were that the money spent on Tamiflu was likely misspent, and moreover the lack of access to clinical trial data more widely is unacceptable.<\/div>\n
<\/div>\n
Richard Bacon MP, member of the Committee of Public Accounts, said in  quote which succinctly sums up how unacceptable the current position is :<\/div>\n